BillionToOne to Participate in the Wells Fargo 21st Annual Healthcare Conference

MENLO PARK, Calif., Sept. 2, 2026 /PRNewswire/ -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that Company management will participate in the Wells Fargo 21st Annual Healthcare Conference.

PRNewsWire • Sep 2, 2026

BillionToOne Launches Northstar Origin, a New Liquid Biopsy Test to Help Identify Tissue of Origin

New add-on test from a single blood draw; BillionToOne also expands Northstar Select® panel to 102 genes MENLO PARK, Calif., Sept. 1, 2026 /PRNewswire/ -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the launch of Northstar Origin™, a new liquid biopsy add-on test for tissue-of-origin prediction, along with the expansion of its Northstar Select® panel from 84 to 102 genes to cover genes that are included in recent and upcoming FDA approvals.

PRNewsWire • Sep 1, 2026

BillionToOne's Co-Founder Sells 10,000 Shares for $1 Million

The transaction involved 10,000 shares at a weighted-average price of $100.00 per share, totaling $1.0 million on the August 25, 2026 transaction date. Following the disposal, the insider holds a direct position of 1,000 shares, which represents approximately 0.0022% of the company's total shares outstanding.

The Motley Fool • Aug 28, 2026

Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions

Study of more than 2,200 pregnant carriers demonstrates strong clinical performance in the intended-use, general-risk population, with outcomes available for more than 98% of eligible cfDNA results MENLO PARK, Calif., Aug. 18, 2026 /PRNewswire/ -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced publication of A Prospective, Multi-Site Study of Performance of Cell-Free DNA Testing for Recessive Conditions in a Large, General-Risk Pregnancy Population in The Green Journal.

PRNewsWire • Aug 18, 2026

BillionToOne: A Softer Quarter After Heightened Expectations

BillionToOne experienced a sharp post-earnings sell-off despite maintaining full-year guidance and strong year-over-year revenue growth. Second quarter results showed slowing sequential growth, softer average selling prices, and significant margin compression versus Q1. The company trades at ~10x sales, a premium to May levels, with the growth story intact but near-term valuation less attractive.

Seeking Alpha • Aug 7, 2026

Why BillionToOne Plummeted 36%, Leading A Medtech Sell-Off

Medical research stocks took a bath Thursday, helped by BillionToOne's second-quarter report, featuring a beat but no guidance raise.

Investors Business Daily • Aug 6, 2026

Billiontoone Q2 Earnings Call Highlights

Billiontoone NASDAQ: BLLN reported second-quarter 2026 revenue growth of 64% year over year, driven by higher testing volumes and average selling prices across its prenatal and oncology businesses. The molecular diagnostics company also posted positive operating income and free cash flow while reiterating its full-year revenue outlook.

MarketBeat • Aug 5, 2026

BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance

MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the second quarter ended June 30, 2026 and reiterated guidance for full year 2026.

GlobeNewsWire • Aug 5, 2026

BillionToOne (BLLN) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for BillionToOne (BLLN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Investment Research • Aug 6, 2026

Read Between These Lines As Eli Lilly, Hot IPO And More Face Key Test

As stocks like Eli Lilly, Twilio, Hinge Health and more move ahead of earnings report, pay attention to these chart lines.

Investors Business Daily • Aug 3, 2026